Compare Novartis AG (NVS) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Vanguard Total Stock Market Index Fund ETF trades at $369.49. The key difference: Novartis AG pays a 3.17% dividend while Vanguard Total Stock Market Index Fund ETF pays none, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | VTI | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | — |
52-Week High | $168.62 | $374.36 |
52-Week Low | $113.50 | $305.74 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
VTI trades at $366.25, down 0.21% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF offers broad exposure to the entire U.S. stock market with over 3,500 holdings and a low 0.03% expense ratio. Recent news highlights its role in long-term portfolios and inclusion in new tax-advantaged accounts, emphasizing diversification benefits.
Outlook remains positive for long-term investors due to historical performance and cost efficiency, but near-term risks include market volatility and potential underperformance if large-cap tech stocks weaken. The bearish technical setup suggests caution for short-term traders, while fundamentals support holding for wealth accumulation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
